Wall Street brokerages forecast that Caladrius Biosciences Inc (NASDAQ:CLBS) will announce earnings per share (EPS) of ($0.38) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Caladrius Biosciences’ earnings. Caladrius Biosciences reported earnings of ($0.40) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 5%. The business is scheduled to report its next quarterly earnings results on Thursday, March 28th.
On average, analysts expect that Caladrius Biosciences will report full-year earnings of ($1.75) per share for the current fiscal year, with EPS estimates ranging from ($1.81) to ($1.69). For the next fiscal year, analysts anticipate that the business will post earnings of ($2.03) per share, with EPS estimates ranging from ($2.36) to ($1.69). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Caladrius Biosciences.
Caladrius Biosciences (NASDAQ:CLBS) last announced its earnings results on Thursday, November 8th. The biotechnology company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.20.
CLBS has been the subject of several research reports. Zacks Investment Research downgraded shares of Caladrius Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, November 12th. HC Wainwright reaffirmed a “buy” rating and set a $18.50 price objective on shares of Caladrius Biosciences in a research note on Thursday, January 24th.
A hedge fund recently raised its stake in Caladrius Biosciences stock. Vanguard Group Inc raised its holdings in shares of Caladrius Biosciences Inc (NASDAQ:CLBS) by 2.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 202,568 shares of the biotechnology company’s stock after buying an additional 5,700 shares during the period. Vanguard Group Inc owned about 2.06% of Caladrius Biosciences worth $1,196,000 at the end of the most recent reporting period. 7.73% of the stock is owned by institutional investors.
Shares of NASDAQ CLBS opened at $5.10 on Friday. Caladrius Biosciences has a 1 year low of $3.05 and a 1 year high of $11.65.
About Caladrius Biosciences
Caladrius Biosciences, Inc operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.
Featured Article: Asset Allocation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.